Trials / Recruiting
RecruitingNCT07104565
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A Phase 2a, Open-Label, Multicenter Study of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCA000585 | Tafasitamab will be administered intravenously at protocol defined timepoints. |
Timeline
- Start date
- 2025-12-29
- Primary completion
- 2027-09-23
- Completion
- 2028-03-09
- First posted
- 2025-08-05
- Last updated
- 2026-04-13
Locations
40 sites across 7 countries: United States, Australia, France, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07104565. Inclusion in this directory is not an endorsement.